SCHEMBL8519008

SCHEMBL8519008

CCCCCNOC(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.57
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.48
CES2 O00748 3/20 0.47
CES1 P23141 3/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 2/20 0.47
HTR1A P08908 1/20 0.47
CYP2D6 P10635 1/20 0.47
SCN1A P35498 1/20 0.47
SLC6A3 Q01959 1/20 0.47
SCN5A Q14524 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
EPHX1 P07099 3/20 0.46
HTT P42858 1/20 0.46
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14981917 0.98 NAAA (0.59) NAAALMNATSHRCES2CES1
SCHEMBL14981922 0.98 NAAA (0.59) NAAALMNATSHRCES2CES1
SCHEMBL18196734 0.98 NAAA (0.59) NAAALMNATSHRCES2CES1
SCHEMBL11503257 0.98 NAAA (0.59) NAAALMNATSHRCES2CES1
SCHEMBL16487021 0.97 NAAA (0.58) NAAALMNATSHRCES2CES1
SCHEMBL3492807 0.95 LMNA (0.51) NAAALMNATSHRCES2CES1
SCHEMBL28876438 0.91 MGLL (0.51) NAAALMNATSHRALDH1A1MAPT
SCHEMBL21599106 0.90 MGLL (0.54) NAAALMNATSHRALDH1A1MAPT
SCHEMBL21599094 0.90 MGLL (0.54) NAAALMNATSHRALDH1A1MAPT
SCHEMBL10904247 0.90 KMT2A (0.53) NAAALMNATSHRCES1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0923537-A1 PROCESS FOR THE PREPARATION OF CONTRAST AGENTS NYCOMED IMAGING AS (NO) 1999-06-23 EP claimed
WO-1998008805-A1 PROCESS FOR THE PREPARATION OF CONTRAST AGENTS NYCOMED IMAGING AS (NO) 1998-03-05 WO claimed
CN-117821978-A Preparation method and application method of corrosion inhibitor for improving metal rust prevention capability 马鞍山钢铁股份有限公司 2024-04-05 CN disclosed
US-8735622-B2 Histone demethylase inhibitors and methods for using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2014-05-27 US disclosed
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME The Regents of the University of Colorado, a body corporated (US) 2013-05-30 US disclosed
US-4207330-A Method for treating hyperglycemia in mammals using arylamino benzoic acids THE DOW CHEMICAL COMPANY (US) 1980-06-10 US disclosed
US-4143151-A METHOD FOR TREATING HYPERGLYCEMIA IN MAMMALS USING ARYLAMINO BENZOIC ACIDS THE DOW CHEMICAL COMPANY (US) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME KDM1A, KDM3A, KDM7A NAAA 325/4885LMNA 641/4885TSHR 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.